Cargando…

Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours

A pharmacokinetic–pharmacodynamic study was carried out to investigate the feasibility and potential importance of therapeutic monitoring following high-dose carboplatin treatment in children. High-dose carboplatin was administered over 3 or 5 days, with the initial dose based on renal function, to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veal, G J, Errington, J, Tilby, M J, Pearson, A D J, Foot, A B M, McDowell, H, Ellershaw, C, Pizer, B, Nowell, G M, Pearson, D G, Boddy, A V
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360071/ https://www.ncbi.nlm.nih.gov/pubmed/17299395 http://dx.doi.org/10.1038/sj.bjc.6603607

Ejemplares similares

Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
por: Peng, B., et al.
Publicado: (1997)

Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – a study of the United Kingdom Children's Cancer Study Group
por: Veal, G J, et al.
Publicado: (2007)

Estimation of renal function and its potential impact on carboplatin dosing in children with cancer
por: Chinnaswamy, G, et al.
Publicado: (2008)

Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis.
por: English, M. W., et al.
Publicado: (1996)

Dose-related nephrotoxicity of carboplatin in children
por: English, M W, et al.
Publicado: (1999)

Generation of evidence-based carboplatin dosing guidelines for neonates and infants
por: Barnett, Shelby, et al.
Publicado: (2023)

Overestimation of carboplatin doses is avoided by radionuclide GFR measurement
por: Craig, A J, et al.
Publicado: (2012)

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.
por: Rankin, E. M., et al.
Publicado: (1992)

Carboplatin therapeutic monitoring in preterm and full-term neonates
por: Veal, Gareth J., et al.
Publicado: (2015)

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
por: Liao, John B, et al.
Publicado: (2021)

Antitumor Activity of the Carboplatin-α-Cyclodextrin Adduct
por: Liu, Weiping, et al.
Publicado: (1997)

Carboplatin and renal function in children.
por: Stevens, M. C., et al.
Publicado: (1991)

Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens
por: Veal, Gareth J., et al.
Publicado: (2016)

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
por: Sharma, R, et al.
Publicado: (2009)

Estimation of glomerular filtration rate in paediatric cancer patients using (51)CR-EDTA population pharmacokinetics
por: Cole, M, et al.
Publicado: (2004)

Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer
por: Willits, I, et al.
Publicado: (2005)

Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
por: Ma, J., et al.
Publicado: (1995)

Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells
por: Armstrong, J L, et al.
Publicado: (2005)

Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
por: Korst, A. E., et al.
Publicado: (1997)

Benzene adducts with rat nucleic acids and proteins: dose-response relationship after treatment in vivo.
por: Mazzullo, M, et al.
Publicado: (1989)

Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice
por: Akgül, Seçkin, et al.
Publicado: (2022)

CARBOPLATIN DOSING FOR ADULT JAPANESE PATIENTS
por: ANDO, YUICHI, et al.
Publicado: (2014)

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
por: O'Neill, V J, et al.
Publicado: (2002)

Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models
por: Porter, L. H., et al.
Publicado: (2023)

Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopy.
por: Meijer, C., et al.
Publicado: (1997)

Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience
por: Schrama, J G, et al.
Publicado: (2003)

Structural basis for the sequence-dependent effects of platinum–DNA adducts
por: Ramachandran, Srinivas, et al.
Publicado: (2009)

Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8).
por: Peckham, M. J., et al.
Publicado: (1985)

Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers
por: Samani, A., et al.
Publicado: (2022)

Antitumor Trans Platinum Adducts of GMP and AMP
por: Liu, Yangzhong, et al.
Publicado: (2000)

Letter comments on: Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers
por: Cartwright, D., et al.
Publicado: (2022)

Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin
por: Meczes, E L, et al.
Publicado: (2002)

Carboplatin Dosing in Children Using Estimated Glomerular Filtration Rate: Equation Matters
por: van de Velde, Mirjam E., et al.
Publicado: (2021)

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
por: Glasspool, R M, et al.
Publicado: (2014)

Acetaminophen-cysteine adducts during therapeutic dosing and following overdose
por: Heard, Kennon J, et al.
Publicado: (2011)

Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer
por: Kloft, C, et al.
Publicado: (2003)

High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.
por: Lyttelton, M. P., et al.
Publicado: (1998)

p53-mediated delayed NF-κB activity enhances etoposide-induced cell death in medulloblastoma
por: Meley, D, et al.
Publicado: (2010)

A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy
por: Kohler, J A, et al.
Publicado: (2000)

Monofunctional and Interstrand DNA Adducts of Platinum(II) Complexes
por: Brabec, Viktor, et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_0o4kp14cm3i2q281muiitbmvi4